Related ArticlesOlaparib in the treatment of ovarian cancer. Future Oncol. 2019 Sep 03;: Authors: Washington CR, Richardson DL, Moore KN Abstract The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-associated epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond. Women who are diagnosed with advanced stage EOC face a formidable challenge...
Wed Sep 04, 2019 16:27
Publication date: November–December 2019Source: Reports of Practical Oncology & Radiotherapy, Volume 24, Issue 6Author(s): Sarah Barrett, Pierre Thirion, Dean Harper, Andrew J. Simpkin, Michelle Leech, Kim Hickey, Laoise Ryan, Laure MarignolAbstractAimThis study aimed to evaluate the dosimetric impact of uncorrected yaw rotational error on both target coverage and OAR dose metrics in this patient population.BackgroundRotational set up errors can be difficult to correct in lung VMAT SABR treatments,...
Wed Sep 04, 2019 13:55
Publication date: Available online 3 September 2019Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Yazid Belkacemi, Adrien Paix, Alphonse G Taghian
Wed Sep 04, 2019 13:55
Abstract Little is known about the availability of high-quality online health information (OHI) for adverse effects (AEs) of radiotherapy (RT) and chemotherapy (CHT). Optimal search strategies for gaining access to high-quality OHI for these topics are not well-established. This study explores the quality of, potential disparities in, and possible search strategies for OHI pertaining to AEs of RT and CHT. One hundred twenty phrases on generalized and malignancy site-specific AEs...
Mon Sep 02, 2019 03:00
Abstract Undifferentiated pleomorphic sarcoma (UPS) is the second most common soft tissue sarcoma. For patients with unresectable or metastatic disease, chemotherapies are considered, but in many cases they are not curative. There is a need to identify specific molecular dysregulations that can be therapeutic targets. We focused on neurotensin receptor 1 (NTSR1), which belongs to the G‐protein‐coupled receptor. NTSR1 expression was upregulated in specimens from patients with UPS. Real‐time polymerase...
Tue Sep 03, 2019 13:39
Renal cell carcinoma (RCC) is a deadly urological tumor that remains largely incurable. Our limited understanding of key molecular mechanisms underlying RCC invasion and metastasis has hampered efforts to iden...
Tue Sep 03, 2019 03:00
Publication date: October 2019Source: Cancer Epidemiology, Volume 62Author(s): Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Vincas Urbonas, Giedre SmailyteAbstractPurposeWe aimed to assess oncological outcomes in colorectal cancer patients with type 2 diabetes mellitus (T2DM) using metformin.MethodsPatients with colorectal cancer and T2DM during 2000–2012 period were identified form Lithuanian Cancer Registry and the National Health Insurance Fund database....
Wed Sep 04, 2019 12:25
Cancers, Vol. 11, Pages 1300: Assessing Cachexia Acutely after Autologous Stem Cell Transplant Cancers doi: 10.3390/cancers11091300 Authors: Lindsey J. Anderson Chelsea Yin Raul Burciaga Jonathan Lee Stephanie Crabtree Dorota Migula Kelsey Geiss-Wessel Haiming M. Liu Solomon A. Graf Thomas R. Chauncey Jose M. Garcia Autologous hematopoietic stem cell transplantation (AHCT) is an accepted strategy for various hematologic malignancies that can lead to functional...
Wed Sep 04, 2019 03:00
Background The effectiveness of colorectal cancer screening with fecal immunochemical tests (FITs) of stool blood depends on high rates of colonoscopy follow‐up for abnormal FITs and the use of high‐quality tests. This study characterized colonoscopy referral and completion among patients with abnormal FITs and the types of FITs implemented in a sample of Southern California Federally Qualified Health Centers (FQHCs). Methods FQHCs in San Diego, Imperial, and Los Angeles Counties were invited...
Tue Sep 03, 2019 19:03
Tue Sep 03, 2019 19:03
Cetuximab and panitumumab bind the human epidermal growth factor receptor (EGFR). While the chimeric cetuximab (IgG1) triggers antibody‐dependent‐cellular‐cytotoxicity (ADCC) of EGFR positive target cells, panitumumab (a human IgG2) does not. The inability of panitumumab to trigger ADCC reflects the poor binding affinity of human IgG2 Fc for the FcγRIII (CD16) on natural killer (NK) cells. However, both human IgG1 and IgG2 bind the FcγRII (CD32A) to a similar extent. This study compares the ability...
Tue Sep 03, 2019 19:35
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti‐PD‐1/PD‐L1 therapeutic biomarkers and protein markers of potential chemotherapy response. Data was extracted from a clinical‐grade testing database (Caris Life Sciences; February 2015 through November 2017): immunotherapy response markers (microsatellite instability high (MSI‐H), tumor mutation burden‐high (TMB‐H), and PD‐L1 protein expression; and protein...
Tue Sep 03, 2019 19:32
Patient‐derived xenograft (PDX) models are widely used as preclinical cancer models and are considered better than cell culture models in recapitulating the histological features, molecular characteristics and intratumoral heterogeneity (ITH) of human tumors. While the PDX model is commonly accepted for use in drug discovery and other translational studies, a growing body of evidence has suggested its limitations. Recently, the fidelity of cancer cells within a PDX has been has been questioned, which...
Tue Sep 03, 2019 19:09
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου